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Abstract
Background: Clinical management of primary ciliary dyskinesia (PCD) respiratory disease is currently based on improving
mucociliary clearance and controlling respiratory infections, through the administration of antibiotics. Treatment practices
in PCD are largely extrapolated from more common chronic respiratory disorders, particularly cystic fibrosis, but
no randomized controlled trials (RCT) have ever evaluated efficacy and safety of any pharmacotherapeutics used
in the treatment of PCD. Maintenance therapy, with the macrolide antibiotic azithromycin, is currently widely used in
chronic respiratory diseases including PCD. In addition to its antibacterial properties, azithromycin is considered to have
beneficial anti-inflammatory and anti-quorum-sensing properties.
The aim of this study is to determine the efficacy of azithromycin maintenance therapy for 6 months on respiratory
exacerbations in PCD. The secondary objectives are to evaluate the efficacy of azithromycin on lung function, ventilation
inhomogeneity, hearing impairment, and symptoms (respiratory, sinus, ears and hearing) measured on a PCD-specific
health-related quality of life instrument, and to assess the safety of azithromycin maintenance therapy in PCD.
Methods: The BESTCILIA trial is a European multi-centre, double-blind, randomized, placebo-controlled, parallel group
study. The intervention is tablets of azithromycin 250/500 mg according to body weight or placebo administered three
times a week for 6 months. Subjects with a confirmed diagnosis of PCD, age 7–50 years, are eligible for inclusion.
Chronic pulmonary infections with Gram-negative bacteria or any recent occurrence of non-tuberculous mycobacteria
are exclusion criteria. The planned number of subjects to be included is 125. The trial has been approved by the
Research Ethics Committees of the participating institutions.
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Discussion: We present a study protocol of an ongoing RCT, evaluating for the first time, the efficacy and safety of a
pharmacotherapeutic treatment for patients with PCD. The RCT evaluates azithromycin maintenance therapy, a drug
already commonly prescribed in other chronic respiratory disorders. Furthermore, the trial will utilize the Lung clearance
index and new, PCD-specific quality of life instruments as outcome measures for PCD. Recruitment is hampered
by frequent occurrence of Pseudomonas aeruginosa infection, exacerbations at enrolment, and the patients’
perception of disease severity and necessity of additional management and treatment during trial participation.
Trial registration: EudraCT 2013-004664-58 (date of registration: 2014-04-08).
Keywords: Primary ciliary dyskinesia, Azithromycin, Lung clearance index, Multiple breath washout, Health-related
quality of life, QOL-PCD, Exacerbation
Background
Primary ciliary dyskinesia (PCD) is a rare, congenital
disease with symptom onset in the neonatal period or
early childhood, with progression throughout adulthood.
PCD presents with chronic rhino-sinusitis, recurrent otitis
media and conductive hearing impairment, chronic pro-
ductive cough and infection and inflammation of the
lower respiratory tract [1, 2]. The cilia lining the respira-
tory epithelium are either immotile or dyskinetic and
therefore cannot generate coordinated ciliary beating ne-
cessary to expel mucus [3]. The defective mucociliary
clearance causes excessive mucus, bacteria and debris to
accumulate in the airways, serving as a nidus for infection
[4, 5]. Recurrent lower respiratory tract infections progress
to chronic infection that leads to bronchiectasis. PCD
causes loss of lung function and in severe cases, can result
in chronic respiratory failure, with lung transplantation as
the final therapeutic avenue [1, 6]. Ciliary beating is im-
portant in organ systems other than the respiratory tract
such as the embryonic node, sperm flagella, female re-
productive tract, and ependyma of the brain and spinal
cord [3]. Patients with PCD can therefore also present
with situs inversus, reduced fertility, hydrocephalus or,
more rarely, complex congenital heart disease. PCD is a
genetically heterogeneous disorder, which is predomin-
antly inherited as autosomal recessive trait [1, 7]. Rough
estimates of the prevalence of PCD indicate that it affects
1 in 10.000–20.000 individuals [2, 8]. PCD respiratory
disease shares some similarities with cystic fibrosis (CF),
in which mucociliary clearance is also impaired [9].
As with all chronic respiratory diseases, the aim of
treatment for PCD is to maintain or restore normal lung
function to the extent possible. The clinical management
of PCD respiratory disease is focused on improving
mucociliary clearance, primarily with chest physiother-
apy, and controlling respiratory infections through the
administration of antibiotics [1, 6, 10, 11]. No orphan
drugs are available for the treatment of PCD, and the
current treatment practices in PCD are extrapolated
from treatment of other chronic respiratory disorders, par-
ticularly CF, and therefore based on the pathophysiology of
these diseases. This strategy is questionable since PCD ex-
hibits a different pathophysiology [1, 12]. No randomized
controlled trials (RCT) have been conducted in PCD to de-
termine the efficacy and safety of those pharmacotherapeu-
tics currently used; and thus there are no evidence-based
guidelines for pharmacotherapy of PCD patients [1, 11].
Accordingly, management strategies for PCD vary widely
between and within the European countries [12]. The lack
of evidence for management of PCD respiratory disease is a
likely reason for the poor clinical impact on preventing de-
cline in lung function - even when diagnosis is made at an
early age [8]. Appropriate treatment of PCD will likely re-
duce the morbidity of PCD and prolong the life expectancy
of PCD-patients.
There is anecdotal evidence of positive outcomes of
long-term prophylactic antibiotic treatment in PCD
[10, 11]. Over the last decade, maintenance therapy
with macrolide antibiotics has been studied in a number
of trials in different chronic respiratory diseases, following
evidence of effectiveness of low-dose long-term therapy
with erythromycin in diffuse panbronchiolitis [13]. In
addition to its antibacterial properties, the macrolide anti-
biotic azithromycin is considered to have beneficial prop-
erties with respect to anti-inflammation and quorum
sensing inhibition [13–15]. Azithromycin has a simple
dosing schedule and covers a wide range of bacteria en-
countered in PCD respiratory infections. A Cochrane re-
view [16] has reported a meta-analysis evaluating the
efficacy and safety of azithromycin maintenance therapy
in CF patients. RCTs examining azithromycin versus
placebo demonstrated improvement in lung function after
a treatment period of 6 months and a significant reduction
in the need for additional oral antibiotics in those patients
receiving azithromycin. Patients receiving azithromycin
were also approximately twice as likely to be free of pul-
monary exacerbation at six months [16]. Adverse events
were uncommon, although more frequent gastrointestinal
events were reported in one trial. Azithromycin main-
tenance therapy, however, has been associated with an
increase in resistance to macrolides [16, 17]. Two RCTs
investigating azithromycin maintenance therapy versus
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placebo in adult patients with non-CF bronchiectasis
for 6 and 12 months, respectively, have been published
[18, 19] and showed decreases in exacerbations, whereas
improvement in lung function, measured by spirometry,
and health-related quality of life was only found in the
12 month RCT. Azithromycin maintenance therapy was
generally well-tolerated, although gastrointestinal symp-
toms were reported more frequently in the azithromycin
group [18, 19]. Decreases in exacerbations attributable to
long-term azithromycin therapy were also demonstrated
in a RCT with Indigenous children with non-CF bronchi-
ectasis or chronic suppurative lung disease [20]. Azithro-
mycin maintenance therapy has also been shown to have
efficacy in chronic obstructive pulmonary disease. How-
ever, hearing decrements were observed to be more com-
mon in the azithromycin group in a 12 month RCT in
patients with chronic obstructive pulmonary disease [21].
Azithromycin maintenance therapy is currently widely
used in the treatment of patients with CF [14, 22] and
other chronic respiratory diseases including PCD, however
there is no evidence to support its use in PCD.
Aims
This trial will generate the first evidence-based know-
ledge on pharmacotherapy in PCD. The main objective
is to determine the efficacy of azithromycin maintenance
therapy for 6 months on respiratory system exacerba-
tions in subjects with PCD, 7–50 years of age.
The secondary objectives of this trial are to:
 Determine the efficacy of azithromycin on lung
function measured by spirometry, on static lung
volumes and airways resistance measured by body
plethysmography, and on ventilation inhomogeneity
measured by nitrogen multiple breath washout
(N2 MBW) as a new outcome measure;
 Assess the efficacy of azithromycin on respiratory,
sinus and ear symptoms as measured by new,
PCD-specific health-related quality of life outcome
measure (QOL-PCD) [23];
 Determine the efficacy of azithromycin on hearing
impairment;
 Determine the efficacy of azithromycin on sputum
microbiology and inflammatory markers;
 Assess the safety of azithromycin maintenance
therapy in PCD.
This study tests the hypothesis that maintenance therapy
with azithromycin provides significant improvement in
PCD respiratory disease compared to placebo, by reducing
respiratory system exacerbations and by improving lung
function, ventilation inhomogeneity, health-related quality
of life and hearing impairment. Maintenance therapy with
azithromycin is expected to be safe with no serious adverse
events compared to placebo.
Methods/Design
Study design
This study is a multi-centre, parallel group, double-blind,
randomized, placebo-controlled trial with azithromycin
maintenance therapy in subjects with PCD (Fig. 1).
Eligibility
Inclusion criteria for the trial are a confirmed diagnosis
of PCD; age 7–50 years; forced expiratory volume in one
second (FEV1) above 40 % predicted at screening; at
least 30 days of treatment with antibiotics prescribed
against respiratory tract infections or exacerbations in
the previous 2 years; no treatment with azithromycin
within 1 month prior to screening; and no current treat-
ment with systemic or inhaled maintenance antibiotics.
A confirmed diagnosis of PCD in this trial is based on
the following: characteristic clinical symptoms and high
speed video microscopic recordings of abnormal ciliary
beat pattern and/or frequency, in combination with either
an abnormally low nasal NO production <77 nl/min [24],
abnormal ciliary ultra-structure demonstrated by trans-
mission electron microscopy analysis or high resolution
immunofluorescence (isolated inner dynein arm defects is
Fig. 1 Trial flow chart
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not accepted), and/or a genetic mutation recognized to
cause PCD.
Exclusion criteria are infection with non-tuberculous
mycobacteria, Achromobacter xylosoxidans, Burkholderia
cepacia or chronic infection with Pseudomonas aeruginosa
(chronic infection with Pseudomonas aeruginosa is in this
trial defined as culture of Pseudomonas aeruginosa in at
least half of the sputum cultures within the last year pro-
vided that at least three sputum cultures are available);
allergic reaction to macrolides or any of the ingredients of
the azithromycin or placebo tablets; alanine transaminase
twice or more the upper limits of normal or history of
portal hypertension; serum creatinine above 150 μmol/l or
GFR above 50 ml/min; congenital or acquired prolonged
QT interval, cardiac arrhythmia, clinical relevant brady-
cardia, severe heart failure or electrolyte disturbances;
myasthenia gravis; current treatment with certain other me-
dicinal products known to possibly interact with azithromy-
cin or to prolong QT interval; pregnancy, breastfeeding or
for women use of unreliable forms of contraception; or
requirement of home oxygen or assisted ventilation.
Recruitment
Eligible patients are identified from six European PCD
outpatient clinics (see Table 1). Patients and their parents
are approached and informed consent obtained.
Intervention
The intervention is oral tablets of azithromycin or iden-
tical tablets of placebo administered three times a week
(Monday-Wednesday-Friday) for 6 months. The dose of
azithromycin is 250 mg for participants with a body
weight below 40 kg at screening and 500 mg for partici-
pants weighting 40 kg or above, corresponding to a weekly
dose of 750 mg or 1500 mg azithromycin, respectively.
Systemic or inhaled antibiotic treatment, besides the
potential azithromycin maintenance therapy during the
trial, is only allowed if needed during clinical exacerba-
tions and in the case of new infection with Pseudomonas
aeruginosa, Achromobacter xylosoxidans or Burkholderia
complex. Treatment of respiratory system exacerbations,
if culture and antibiotic susceptibility is not yet known,
will be 14 days of oral amoxicillin with clavulanic acid as
first-line treatment and clarithromycin as second choice.
More severe exacerbations will be treated according to
local guidelines. Treatment of first time or intermittent
colonization with Pseudomonas aeruginosa will be inhal-
ation of colistin in combination with oral ciprofloxacin
or inhalation of Tobramycin for 3-4 weeks. In case of
treatment failure, early relapse or signs of development
of chronic Pseudomonas aeruginosa infection, antibiotic
treatment will be intensified to last for 3 months. Treat-
ment with the trial medication will continue throughout
the trial simultaneously with any antibiotics prescribed for
exacerbations or infection with Pseudomonas aeruginosa.
Any other pre-trial medication will continue unchanged,
and any other new prescriptions, which are considered
necessary for the participant’s welfare, may be given.
Randomization, allocation and blinding
Participants will be randomly assigned to one of the two
treatment arms in a 1:1 ratio with stratification according
Table 1 Eligible patients and recruitment plans
Trial sites: Estimated no. of eligible
patients:
Recruitment strategies:
Copenhagen University Hospital, Rigshospitalet, Denmark 30 - Patients attending the outpatient clinic.
- Information at PCD patient event.
University Children's Hospital Muenster, Germany 30 - Patients attending the outpatient clinic.
- Advertisement via the national PCD patient organization.
- Information through the German Pediatric
Pulmonology Society.
Inselspital Bern, Switzerland 10 - Patients attending the outpatient clinic.
- Information to patients in the national PCD registry.
VU University Medical Center Amsterdam, Netherlands 20 - Patients attending the outpatient clinic.
- Advertisement via the national PCD patient organization.
- Contacting pediatric pulmonologists caring for
PCD patients at other academic centers.
University Hospital Southampton, United Kingdom 10 - Patients attending the outpatient clinic.
- Advertisement via the national PCD patient organization.
Royal Brompton Hospital, United Kingdom 40 - Patients attending the outpatient clinic.
- Advertisement via the national PCD patient organization.
Total 140
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to age (7–12 years; 13–21 years; and 22–50 years). The
allocation sequence is a permuted-block randomization
and has been generated by an external consultancy
(Datamanagement, Public Health and Quality Improve-
ment, Central Denmark Region, Aarhus, Denmark). Par-
ticipants will be assigned to the intervention by delegated
study staff via an online randomization module in an elec-
tronic Case Report Form (‘TrialPartner’, Datamanagement,
Denmark). The allocation is concealed to the investigative
staff and sponsor throughout the study, and unblinding
will only occur in the event of a Suspected Unexpected
Serious Adverse Reaction or if otherwise required for
patient safety.
A hospital pharmacy (Apotheek Haagse Ziekenhuizen,
The Hague, The Netherlands) is responsible for prepar-
ation of the trial medication. Azithromycin tablets bought
from a pharmaceutical company are repackaged and iden-
tical placebo tablets are specifically manufactured by the
hospital pharmacy. Blinded labelling and packaging of the
trial medication in identical blister packages in carton
boxes is performed centrally at the hospital pharmacy ac-
cording to Good Manufacturing Practice. Adherence to
the trial treatment will be assessed by participant/parent
report and count of returned trial medications.
Data collection
Participants will be screened for eligibility in a stable
state after having given informed consent to participa-
tion. At screening, demographic information (age, gender,
ethnicity) will be recorded and inclusion- and exclusion cri-
teria review will be performed, including data on medical
history, current symptoms and concomitant medication,
physical examination, pregnancy test, electrocardiogram,
spirometry, and sputum microbiology. The QOL-PCD [23]
will be completed by participants both one week prior to
screening and again at the screening visit to obtain baseline
values. Screening will be followed by a run-in period of one
month to ensure that participants have stable lung function
(defined as maximal decrease in FEV1% predicted of 10
percentage points from the screening visit to the
randomization visit) and that prohibited medications
are washed out at randomization. Participants will be
withdrawn prior to randomization if they have an ex-
acerbation or receive systemic or inhaled antibiotics at
the screening or randomization visit, or if they have re-
ceived antibiotics for more than 2 weeks during the
run-in period. Participants will be reviewed every two
months during the 6 months treatment period. Partici-
pants will be asked to contact the trial site at the onset
of an exacerbation, if possible, and exacerbations will
be reviewed at extra visits or by telephone contact.
Withdrawal of participants during the trial will occur if
the participants fulfil any of the exclusion criteria or
due to safety reasons. A QOL-PCD will be completed
by the participants, as a follow-up assessment 2 months
after the end of the treatment period.
All data will be recorded in an electronic case report
form. The primary and secondary outcome measures
(see below) are collected at the specified time points. All
adverse events occurring from the first administration of
the trial medication to the end of the last trial visit will
be recorded and monitored (Table 2).
Outcomes
Primary outcome
Number of exacerbations The primary outcome is the
number of respiratory system exacerbations occurring
during the treatment period. A respiratory system ex-
acerbation is defined in this trial as either respiratory
tract symptoms leading to start of systemic antibiotic
treatment, irrespective of results of bacterial culture, or
as a decline in FEV1% predicted equal to or above 10
percentage points relative to the average of FEV1% pre-
dicted at screening and randomization, whether or not
antibiotics are prescribed.
The occurrence of exacerbations will be assessed by
patient interview, physical examination and spirometry.
At each trial visit, and at any extra contacts with the trial
sites attributable to exacerbations, the participants will
be interviewed regarding symptoms and concomitant
medication since last contact with the trial site. The
interview will be supplemented by a weekly patient diary
on symptoms and antibiotics. A physical examination
reviewing the participants’ general condition, vital signs,
ears, heart and lungs will be performed at all visits.
Secondary outcomes
Lung function measured by spirometry Spirometry
will be performed according to the American Thoracic
Society/European Respiratory Society (ATS/ERS) criteria
[25] at each visit. The outcomes from spirometry are
FEV1, forced vital capacity (FVC) and forced expiratory
flow at 25–75 % of FVC with results expressed in per-
centage of predicted [26]. Short and long acting bron-
chodilators and anticholinergics will be withheld 6 and
12 h prior to spirometry, respectively.
Static lung volumes & airways resistance Measure-
ment of residual volume (RV)% predicted, RV/total lung
capacity (TLC)% predicted and airway resistance (Raw)%
predicted by body plethysmography will be performed at
all trial visits during the 6 month treatment period using
a standardised whole-body plethysmograph and according
to ATS/ERS recommendations [27].
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Ventilation distribution inhomogeneity Assessment of
ventilation distribution inhomogeneity by nitrogen mul-
tiple breath washout (N2 MBW) will be performed at all
the trial visits during the treatment period. The outcomes
derived from N2MBW will be lung clearance index (LCI),
which is a measurement of overall ventilation inhomogen-
eity in the lungs, and the indexes SacinxVT and ScondxVT
reflecting ventilation inhomogeneity in the small conduct-
ing and acinar airways, respectively. N2 MBW will be
measured according to ERS/ATS Consensus Statement
for inert gas washout measurement [28] and will be per-
formed prior to spirometry. All trial sites will use the in-
strument EXHALYZER®D (ECO MEDICS AG, Duernten,
Switzerland) to perform N2 MBW, and results of the N2
MBW will be analysed using the software ‘Spiroware’
(ECO MEDICS AG, Duernten, Switzerland).
Health-related quality of life Newly developed, PCD-
specific health-related quality of life questionnaires (QOL-
PCD) will be used to assess patient-reported outcomes
[23]. The QOL-PCD has age-appropriate versions avail-
able for children 6–12 years, adolescents 13–17 years,
adults, and a parent proxy. The following domains on the
QOL-PCD will be used as outcome measures: Respiratory
Symptoms, Sinus Symptoms, and Ears and Hearing. The
QOL-PCD is available in the primary languages of the par-
ticipating countries (English, Danish, Dutch, German and
Swiss German), and an electronic speaking questionnaire
is available for the youngest age group. The QOL-PCD
will be completed at all visits, at extra contacts with trial
sites attributable to exacerbations, and will be adminis-
tered prior to any other study procedures to reduce bias.
Hearing impairment Audiometry and tympanometry
will be performed at randomization and at the end of
the treatment period at local hospital departments of
otorhinolaryngology. Hearing thresholds will be deter-
mined as the pure tone average at 0.5, 1, 2, 4 & 8 kHz
measured by air conduction and as discrimination loss.
Bone conduction thresholds will only be measured if air
conduction thresholds are above 10 dB.
Sputum microbiology Sputum will be sampled at all visits
for culture of bacteria and fungi. When the participant
Table 2 Time and events schedule
Screening Treatment period Follow-up
Visit
0 months
Visit
1 month
(+2 weeks)
Visit
3 months
(+/- 1 week)
Visit
5 months
(+/- 1 week)
Visit
7 months
(+/- 1 week)
9 months
Informed consent X
Demographics X
Inclusion/Exclusion criteria review X
INTERVENTION:
Randomization X
Azithromycin/Placebo
Adherence X X X
ASSESSMENTS:
QOL-PCD X X X X X X
Patient interview X X X X X
Concomitant medication X X X X X
Weekly patient diary X X X X
Physical examination & vital signs X X X X X
Pregnancy test X X X X X
Electrocardiogram X
Spirometry X X X X X
Body plethysmography X X X X
N2 MBW X X X X
Audiometry & tympanometry X X
Sputum microbiology & antibiotic susceptibility X X X X X
Inflammatory markers (sputum & blood) X X
Blood samples (bone marrow, liver & kidney) X X
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cannot cough up sputum voluntarily, then sampling of
sputum is performed according to local procedures e.g. by
use of cough swabs or by laryngeal suction. Sputum will be
cultured for at least the following microorganisms: Strepto-
coccus pneumonia, Group A beta-haemolytic Streptococcus,
Staphylococcus aureus, Moraxella catharrhalis, Haemophi-
lus influenzae, Pseudomonas aeruginosa, Burkholderia cepa-
cia complex, Achromobacter xylosoxidans and Aspergillus
fumigatus. Microscopy of bacteria will not be performed.
During an exacerbation, participants will be asked to deliver
sputum samples, which, in addition to regular cultures, will
be analysed for respiratory viruses and mycoplasma pneu-
moniae by polymerase chain reaction. The testing will
include the following viruses: Influenza A and B, rhino virus,
adenovirus, respiratory syncytial virus, bocavirus, enterovirus,
metapneumovirus and parainfluenza virus. Culture incl. anti-
biotic susceptibility testing and polymerase chain reaction
are performed at the local microbiological laboratories.
Inflammatory markers In those participants who can ex-
pectorate sputum and in participants where laryngeal suc-
tion is performed, a sample of sputum from randomization
and from the end of the treatment period will be stored in
a biobank for later analysis of cytokines and neutrophil elas-
tase. Blood samples will be taken at simultaneous time
points for measurement of C-reactive protein, white cell
count including differential cell counts and cytokines. C-
reactive protein and white cell count including differential
counts will be analysed in the local hospital laboratories.
The blood samples for measurement of cytokines will be
centrifuged at the local hospital laboratories to isolate the
serum, and the serum will be kept in a biobank for later
analysis. After the end of the trial, all the serum samples
and sputum samples will be analysed for cytokines and
neutrophil elastase collectively at the Department of
Clinical Microbiology at Rigshospitalet in Denmark.
Adverse events Participants will be assessed for the oc-
currence of adverse events using the following measures:
Interview regarding any new or worsening of symptoms;
physical examination including vital signs; microbio-
logical analysis of sputum and antibiotic susceptibility
testing; audiometry; and blood samples to monitor bone
marrow, liver and kidney function. Interview, physical
examination, and culture of sputum and antibiotic sus-
ceptibility testing will be performed at all visits, whereas
audiometry and blood sampling will only be performed
at randomization and at the end of the treatment period.
At screening and end of the treatment period, sputum
will be tested for non-tuberculous mycobacteria [29, 30].
The antibiotic susceptibility testing will at least include
susceptibility of bacteria to azithromycin and either
amoxicillin with clavulanic acid or penicillin (depending
on the bacterial species). The blood samples will include
determination of haemoglobin, white cell count, throm-
bocytes, alanine transaminase and creatinine and will be
analysed in the local hospital laboratories.
An independent data and safety monitoring board will
monitor patient safety and treatment efficacy data while
the trial in ongoing.
Sample size
The planned number of participants to be enrolled in
the trial is 125. The sample size is calculated based on
the primary endpoint and has been estimated based
upon detecting a 50 % reduction in number of exacerba-
tions (assuming a mean of 2.5 exacerbations per year in
the placebo group) in the azithromycin group with a
statistical power of 90 % and assuming Poisson distribu-
tion. On this basis, a sample size of 100 participants
completing the trial will be required, with 50 partici-
pants in each treatment arm. Allowing for a dropout
rate of 20 %, the total number of participants to be en-
rolled in the trial is 125. Power is 70 % to detect a differ-
ence of 5 percentage points between treatments in the
pre- to post-intervention change in FEV1 % predicted
(assuming a SD of 10 % for intra-subject change); and
power is 88 % to detect a difference of 5 percentage
points in the pre- to post-intervention change in LCI
(assuming a SD of 8 % for intra-subject change). Calcu-
lations of power are based on two-sided testing with an
alpha level of 0.05.
Statistical analysis
Two analysis populations are defined: Intention-to-treat
population and per-protocol population. All participants
who are randomized will be included in the intention-
to-treat population analysis, and all available data from
drop-outs will be included in this intention-to-treat ana-
lysis. The per-protocol population analysis will include
all participants, who are randomized, have completed
the trial, have not been discontinued from treatment,
and have had no major protocol deviations. A partici-
pant will be considered to have completed the trial if he
or she has completed all the five visits. The per-protocol
population will be determined prior to unblinding.
Data will be summarized descriptively. For continuous
variables, descriptive statistics such as mean and SD, or
median and range (depending on normality) will be
summarised. For categorical variables, the frequency will
be presented. Analysis of the primary and secondary out-
comes will be based on the intention-to-treat population
and will be repeated based on the per-protocol popula-
tion. The primary outcome will be analysed using Poisson
regression, with adjustment for age as a potential con-
founder. The continuous secondary outcomes will be
modelled using a linear mixed model including a fixed
time-specific treatment effect and random effects of trial
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site and person. Additional potential confounders, such as
age, can be adjusted by including them in the linear mixed
model as fixed main effects. The categorical secondary
outcomes will be analysed by McNemar’s test or test of
marginal homogeneity, as appropriate. All statistical infer-
ence tests will be performed using two-sided testing with
a significance level (alpha) of 0.05. No adjustment will be
made to the significance level for the multiple statistical
comparisons planned as part of the secondary analyses.
Discussion
This RCT will be the first to evaluate the efficacy and
safety of a commonly prescribed maintenance therapy in
PCD, with the potential to improve the clinical manage-
ment of PCD by providing the first evidence base for
pharmacotherapy in this lifelong disease. PCD differs
pathophysiologically and clinically from CF and non-CF
bronchiectasis and therefore, evidence-based guidelines
on pharmacotherapy specifically for PCD are needed.
Besides the burden of recurrent pulmonary infections re-
quiring antibiotic therapy, PCD patients suffer from
chronic daily symptoms of the upper respiratory tract,
including the ears, causing morbidity in everyday life [2]
and potentially interfering with social life and educa-
tional opportunities [23]. Maintenance therapy with po-
tential efficacy for both upper and lower respiratory
tract morbidities is therefore considered highly relevant
for PCD. Azithromycin maintenance therapy is chosen
for this first RCT on pharmacotherapy for PCD because
of its potential anti-inflammatory and antibacterial bene-
fits [13, 15], and its mild side effect profile documented
in previous RCTs of azithromycin maintenance therapy
[16–20]. Additionally, azithromycin is an easily adminis-
tered and inexpensive therapy compared to other candi-
date drugs.
A secondary focus of this trial is the development and
evaluation of new outcome measures in PCD. Since the
treatment intervention in this RCT is directed against
most of the central symptoms of PCD (infections and
impairment in the lungs, sinuses and ears), outcome
measures will be designed to assess several domains of
functioning: respiratory system exacerbations, pulmon-
ary function, health-related quality of life, and hearing
impairment.
The number of respiratory system exacerbations is
chosen as the primary outcome of the trial because it
clearly interrupts normal, everyday activities, requires
additional treatment, and may cause irreversible lung
damage. No consensus definition of exacerbations in
PCD exists, and therefore our definition is based on clin-
ical and patient relevance and feasibility and utility in
clinical practise. Pulmonary function will be assessed by
both traditional spirometry, body plethysmography and
by N2 MBW. RV and RV/TLC ratio measured by body
plethysmography have been shown to correlate with sever-
ity of the total lung impairment on chest high-resolution
computed tomography (HRCT) in PCD and has been
shown to better predict abnormalities on HRCT scans
than spirometric measures [31]. Assessment of ventilation
inhomogeneity by MBW has demonstrated abnormal
values in PCD, even in patients with FEV1 within the nor-
mal range, reflecting small airway disease [32–34], and
one study [34] has shown LCI measured by N2 MBW to
be more sensitive than FEV1 in detecting PCD patients
with structural abnormalities, but there are, however,
contradictory findings on whether LCI correlates with
HRCT scores in PCD [34, 35]. MBW indexes may prove
to be more valuable outcome measures in PCD than the
rather insensitive spirometric parameters. LCI is increas-
ingly being used as outcome measure in CF and has been
shown to have potential as outcome measure in mild CF
lung disease [36, 37].
Finally, we developed patient-reported outcome mea-
sures (PROs) for children, adolescents and adults with
PCD and parent caregivers. PROs are now accepted by
both the FDA and EMA as primary or secondary end-
points in clinical trials and provide unique information
on how new medications and treatments affect daily
symptoms and functioning [38, 39]. These measures as-
sess several domains of health-related quality of life, in-
cluding respiratory and sinus symptoms, physical and
social functioning, and the perceived burden of treat-
ment. PROs have now been routinely incorporated into
randomized trials of new medications in CF and non-CF
bronchiectasis, providing critical information about effi-
cacy and impact on daily functioning [40, 41]. This will
be the first trial to utilize these new PCD-specific PROs.
Hearing impairment will be evaluated by audiometry
and tympanometry partly as an outcome measure for
the efficacy of azithromycin maintenance therapy and
simultaneously also as a safety measure due to reports
of ototoxicity as an adverse reaction of azithromycin
[21, 42]. Besides hearing impairment, emergence of
antibiotic resistance will also be monitored in the trial
as this has been raised as a concern after previous RCTs
with azithromycin maintenance therapy showed in-
creased resistance among common respiratory patho-
gens [18–20, 30].
The challenges of this study may be the wide age range
which includes both paediatric and adult PCD patients,
and differences in routine management between the trial
sites. The trial is designed as a multi-centre study with
participation in several European countries due to the
rarity of PCD. However, even with recruitment at six
trial sites, distributed across five European countries, it
is still necessary to include a wide age range to recruit
enough patients. With regard to the challenge of differ-
ences in routine management between the trial sites, then
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this is reduced by standardising part of the antibiotic treat-
ment regimen per trial protocol and by excluding PCD pa-
tients with chronic Pseudomonas aeruginosa from
participation in the RCT. The decision to exclude patients
with chronic Pseudomonas aeruginosa infection from the
trial is based on the great variation in treatment practises
of Pseudomonas aeruginosa between the participating trial
sites and because chronic infection introduces a high level
of treatment activity, with high dose systemic antibiotic
treatment being the most critical confounder.
The RCT is currently ongoing and participants have
been enrolled at all trial sites. Recruitment is hampered
by our choice to exclude PCD patients with chronic
Pseudomonas aeruginosa infection and patients receiving
systemic or inhaled maintenance antibiotics to limit the
impact of concomitant antibiotic therapy. Pseudomonas
aeruginosa infection has proved to be more common in
PCD than previously anticipated [5]. PCD patients with-
out chronic infection are not used to this frequent and
time consuming follow-up, and, in contrast to CF pa-
tients, PCD patients are in general less well organised in
patient organizations, which seem to influence their
interest in sacrificing time and burden in research (see
Table 3 for reasons for recruitment issues). Scarce know-
ledge on prognosis and clinical sub-phenotypes in PCD
among both physicians and patients probably affects the
perception of disease severity. PCD patients and physi-
cians may have different views on the appropriate extent
of management and treatment, which is important to
take into consideration when designing future trials in
PCD. Another limiting factor for inclusion in this trial is
the requirement of clinical stability at enrolment, which
is challenging in PCD characterized by frequent respiratory
exacerbations and a chronic, but somewhat fluctuating de-
gree of respiratory symptoms. Initially, the protocol did not
allow any change in medication from the screening visit
and throughout the run-in period lasting up to 1½month.
However, we have been forced to allow some oral antibi-
otics during this period. The fluctuating nature of the PCD
disease and the considerable number of patients being on
various more or less permanent antibiotic regimens should
be carefully considered and weighed against the aims of
including only stable and comparable patients, when de-
signing clinical trials in the future.
An issue worth considering in the planning of investi-
gator initiated trials in rare diseases in Europe is the
considerable and time consuming administrative tasks in
conducting European multi-centre trials due to the vari-
ations in application procedures and reporting to the
local authorities, especially the Research Ethics Commit-
tees, of the various European countries, which indeed
does not seem harmonized in the European Member States
despite the EU Clinical Trials Directive (2001/20/EC) [43]
and the Voluntary Harmonisation Procedure [44]. Applica-
tion for administrative support is recommended.
In conclusion, the completion of this RCT will be the
first step towards evidence-based guidelines on pharma-
cotherapy in PCD. Furthermore, the trial will assess the
potential of N2 MBW indexes and newly developed
PCD-specific health-related quality of life questionnaires
as outcome measures in PCD. This RCT will thereby
not only answer the specific research question on the
efficacy and safety of azithromycin maintenance ther-
apy in PCD, but also facilitate future RCTs in PCD by
better developing and evaluating appropriate outcome
measures.
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